EUVIMEDEUVIMED entdecken
Klinische Studie

Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum

Suleima Arruda, Alyssa Swearingen, Zahyaa Elmadany, Anna Nakagama, Emely Alvarado Lemoine, Sophia Clara Valmeus, Neil Sadick

Journal of Drugs in Dermatology · 2025

DOI: 10.36849/jdd.8606 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von Suleima Arruda und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Alopecia, Hair.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: REVIVV® is a topical hair growth serum with a proprietary formula of botanicals that addresses multiple factors involved in hair loss pathophysiology. This open-label, prospective, single-center study evaluated the efficacy of REVIVV®, a topical hair growth serum, in 20 adults (10 male, 10 female) with mild to moderate hair loss over 6 months. Participants applied the serum twice daily, and assessments were conducted at baseline, 4, 12, and 24 weeks. Dermatologist evaluations and patient self-assessments of hair quality and growth were performed using a 7-point Likert scale. Results Investigator-rated improvements in hair quality and growth increased from 0.75 and 0.81 at 4 weeks to 1.73 and 1.83 at 24 weeks, respectively. Patient-reported assessments showed that 85% of participants noted improved hair quality and growth at 24 weeks, with 50% reporting great improvement. Patient satisfaction was high, with 80% of participants being moderately or greatly satisfied at 4 weeks, increasing to 95% at 24 weeks. No adverse events related to the serum were reported throughout the study. The results demonstrate that twice-daily application of REVIVV® over 6 months is associated with increased hair growth and improved hair quality suggesting that REVIVV® may be an effective, non-pharmacological option for individuals seeking to improve hair growth and quality. J Drugs Dermatol. 2025;24(4):394-396. doi:10.36849/JDD.8606 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaHairHumansFemaleMaleProspective StudiesAdultMiddle AgedPatient SatisfactionTreatment OutcomeYoung Adult

Zitieren

APA

Arruda, S., Swearingen, A., Elmadany, Z., Nakagama, A., Lemoine, E. A., Valmeus, S. C., & Sadick, N. (2025). Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8606

Vancouver

Arruda S, Swearingen A, Elmadany Z, Nakagama A, Lemoine EA, Valmeus SC, et al. Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.8606

BibTeX
@article{Arruda2025,
  author = {Arruda, Suleima and Swearingen, Alyssa and Elmadany, Zahyaa and Nakagama, Anna and Lemoine, Emely Alvarado and Valmeus, Sophia Clara and Sadick, Neil},
  title = {Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum},
  journal = {Journal of Drugs in Dermatology},
  year = {2025},
  doi = {10.36849/jdd.8606}
}
Kostenlos starten →